Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
Name | Price | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anti-CCNG2 antibody (20-100 aa) (STJ191665) | Login | Anti-CCNG2 antibody (20-100 aa) (STJ191665) | ||||||||||||||||
|
||||||||||||||||||
Anti-CCNI antibody (30-110 aa) (STJ191666) | Login | Anti-CCNI antibody (30-110 aa) (STJ191666) | ||||||||||||||||
|
||||||||||||||||||
Anti-CCNK antibody (80-160 aa) (STJ191667) | Login | Anti-CCNK antibody (80-160 aa) (STJ191667) | ||||||||||||||||
|
||||||||||||||||||
Anti-CCNL2 antibody (400-480 aa) (STJ191668) | Login | Anti-CCNL2 antibody (400-480 aa) (STJ191668) | ||||||||||||||||
|
||||||||||||||||||
Anti-CCNT1 antibody (220-300 aa) (STJ191669) | Login | Anti-CCNT1 antibody (220-300 aa) (STJ191669) | ||||||||||||||||
|
||||||||||||||||||
Anti-CCNT2 antibody (510-590 aa) (STJ191670) | Login | Anti-CCNT2 antibody (510-590 aa) (STJ191670) | ||||||||||||||||
|
||||||||||||||||||
Anti-CCNY antibody (270-350 aa) (STJ191671) | Login | Anti-CCNY antibody (270-350 aa) (STJ191671) | ||||||||||||||||
|
||||||||||||||||||
Anti-CD27 antibody (1-80 aa) (STJ191672) | Login | Anti-CD27 antibody (1-80 aa) (STJ191672) | ||||||||||||||||
|
||||||||||||||||||
Anti-CDK13 antibody (650-730 aa) (STJ191674) | Login | Anti-CDK13 antibody (650-730 aa) (STJ191674) | ||||||||||||||||
|
||||||||||||||||||
Anti-CDK19 antibody (30-110 aa) (STJ191675) | Login | Anti-CDK19 antibody (30-110 aa) (STJ191675) | ||||||||||||||||
|
||||||||||||||||||
Anti-CDK12 antibody (50-130 aa) (STJ191676) | Login | Anti-CDK12 antibody (50-130 aa) (STJ191676) | ||||||||||||||||
|
||||||||||||||||||
Anti-CD5L antibody (220-300 aa) (STJ191677) | Login | Anti-CD5L antibody (220-300 aa) (STJ191677) | ||||||||||||||||
|
||||||||||||||||||
Anti-CENPI antibody (10-90 aa) (STJ191680) | Login | Anti-CENPI antibody (10-90 aa) (STJ191680) | ||||||||||||||||
|
||||||||||||||||||
Anti-CENPS antibody (70-150 aa) (STJ191687) | Login | Anti-CENPS antibody (70-150 aa) (STJ191687) | ||||||||||||||||
|
||||||||||||||||||
Anti-CENPU antibody (160-240 aa) (STJ191689) | Login | Anti-CENPU antibody (160-240 aa) (STJ191689) | ||||||||||||||||
|
||||||||||||||||||
Anti-CYLC1 antibody (290-370 aa) (STJ191693) | Login | Anti-CYLC1 antibody (290-370 aa) (STJ191693) | ||||||||||||||||
|
||||||||||||||||||
Anti-CYLC2 antibody (280-360 aa) (STJ191694) | Login | Anti-CYLC2 antibody (280-360 aa) (STJ191694) | ||||||||||||||||
|
||||||||||||||||||
Anti-CCNQ antibody (30-110 aa) (STJ191695) | Login | Anti-CCNQ antibody (30-110 aa) (STJ191695) | ||||||||||||||||
|
||||||||||||||||||
Anti-SPAG9 antibody (590-670 aa) (STJ191696) | Login | Anti-SPAG9 antibody (590-670 aa) (STJ191696) | ||||||||||||||||
|
||||||||||||||||||
Anti-MAP3K12 antibody (730-810 aa) (STJ191697) | Login | Anti-MAP3K12 antibody (730-810 aa) (STJ191697) | ||||||||||||||||
|
||||||||||||||||||
Anti-MAP3K14 antibody (90-170 aa) (STJ191698) | Login | Anti-MAP3K14 antibody (90-170 aa) (STJ191698) | ||||||||||||||||
|
||||||||||||||||||
Anti-MAP4K2 antibody (400-480 aa) (STJ191699) | Login | Anti-MAP4K2 antibody (400-480 aa) (STJ191699) | ||||||||||||||||
|
||||||||||||||||||
Anti-MAGEA2/MAGEA2B antibody (50-130 aa) (STJ191701) | Login | Anti-MAGEA2/MAGEA2B antibody (50-130 aa) (STJ191701) | ||||||||||||||||
|
||||||||||||||||||
Anti-MAGEA3 antibody (190-270 aa) (STJ191702) | Login | Anti-MAGEA3 antibody (190-270 aa) (STJ191702) | ||||||||||||||||
|
||||||||||||||||||
Anti-MAGEA6 antibody (10-90 aa) (STJ191703) | Login | Anti-MAGEA6 antibody (10-90 aa) (STJ191703) | ||||||||||||||||
|